natgillin/translations-raw huggingface dataset:
y R8 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted ariloxy, halogen, in the manufacture of a medicament for the treatment and/or prevention of a GSK-3 mediated disease or condition. 
, R8, R9, R10, R11, R13, R14, R15, R16, R17, R18, R19 i R20 se bira između vodika, supstituiranog ili nesupstituiranog alkila, supstituiranog ili nesupstituiranog cikloalkila, supstituiranog ili nesupstituiranog alkenila, supstituiranog ili nesupstituiranog arila, supstituiranog ili nesupstituiranog heterocikla, supstituiranog ili nesupstituiranog alkoksi, supstituiranog ili nesupstituiranog ariloksi, halogena;
and R3 independently are hydrogen, alkyl or together form an oxo group; 
R2 i Rs su zasebno vodik, alkil ili zajedno formiraju okso grupu;
With this arrangement there is a minimum number of components in the outflow end 15, which can also be cleaned easily, optionally by sliding the sleeve 20 off the pipe section 43 and cleaning the outside of the plunger 21 from the outflow channel. FIG. 
Uz takvu izvedbu potreban je minimalan broj komponenti na izlaznom kraju 15, koji se isto tako može lako čistiti, moguće pomicanjem rukavca 20 s dijela cijevi 43 i čišćenja vanjskog dijela klipa 21 iz kanala za istjecanje.
A system of any preceding claim wherein, for each phase contact device, the conduit (3) comprises a region in which the conduit undergoes a change in direction, optionally wherein the conduit comprises two arms which are interconnected by said region, the apparatus being configured for the two arms to be upright and in fluid interconnection at lower ends thereof when the apparatus is in use. 
Sustav sukladno bilo kojem od patentnih zahtjeva, naznačen time, da svaki faznokontaktni uređaj, cjevovod (3) obuhvaća područje u kojem taj cjevovod prolazi kroz promjenu smjera, opcionalno pri čemu taj cjevovod obuhvaća dva kraka koji su međusobno povezana spomenutom regijom, taj aparat je konfiguriran da ta dva kraka budu vertikalna 1 u fluidnoj međusobnoj vezi na njihovim svojim donjim krajevima prilikom uporabu aparata.
A preferred carbonaceous fuel element is a pressed or extruded carbon mass prepared from carbon and a binder, by conventional pressure forming or extrusion techniques. 
Poželjan ugljični gorivi element je prešana ili istisnuta ugljična masa napravljena iz ugljika i vezivnog sredstva, konvencionalnim tehnikama formiranja pod tlakom ili istiskivanja.
The product of claim 8 wherein the activated cysteinamide residue is H-Cys(Npys)-NH2. 
Postupak prema patentnom zahtjevu 9, naznačen time, da aktivirani cisteinamidni ostatak jest H-Cys(Npys)-NH..
The method according to claim 1, wherein the disease or disorder is fallopian cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak gušterače.
A method according to any of the claims 1-4, wherein the collection of binding molecules on the surface of replicable genetic packages is a single chain Fv library. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je kolekcija molekula za vezanje na površini replikativnih genetskih paketa Fv zbirka jednostrukog lanca.
The method according to Claim 9, wherein R1a represents an optionally substituted benzoyl group; and R2a represents an optionally substituted benzoyl group. 
Metoda prema patentnom zahtjevu 9, gdje R1a predstavlja po izboru supstituiranu benzoil grupu; i R2a predstavlja po izboru supstituiranu benzoil grupu.
A process for preparing a pharmaceutical formulation comprising combining any one or a combination of the Desfesoterodine succinate salts and/or solid state forms thereof according to any one of claims 1 to 8, or the pharmaceutical composition according to claim10, and at least one pharmaceutically acceptable excipient. 
Postupak pripreme farmaceutskog oblika koji sadrži kombiniranje bilo koje ili kombinacije sukcinatnih soli desfesoterodina i/ili njihovih oblika u čvrstom stanju prema bilo kojem od zahtjeva 1 do 8, ili farmaceutski pripravak prema zahtjevu 10, 1 barem jednu farmaceutski prikladnu pomoćnu tvar.
An optical navigation system comprising; 
Sustav za optičku navigaciju (10), naznačen time što sadrži:
The phacoemulsification tip of claim 1, wherein the lateral displacement of the tip at the distal end point (106) of the tip is approximately in a range of 40 to 200 microns. 
Fakoemulzifikacijski vrh prema zahtjevu 1, naznačen time, da je bočno premještanje vrha na točki distalnog kraja (106) od vrha, otprilike u rasponu od 40 do 200 mikrona.
The process according to any one of claims 1 to 4, characterized in that the furan derivative is 5-hydroxymethylfurfural. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je derivat furana 5-hidroksimetilfurfural.
Paragraph 51. The method of Paragraph 50, wherein Y is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1H-pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil; Y je opcijski supstituiran aril ili opcijski supstituiran heteroaril koji može biti opcijski supstituiran sa 1-3 supstituenta nezavisno odabrana od halo, Cy-Ca alkila, halogeniranog C;-C, alkila, ili C,-C, alkoksi;
means absolute S configuration 
(S) znači apsolutna S konfiguracija.
is 1 to 5 amino acid residues in length; and 
L; je duljine 1 do 5 ostataka amino kiseline; i
supplying the injection material to the auxiliary injection line on one side of the assembly; 
- < dovođenje injekcijskog materijala do pomoćne injekcijske linije (25) na jednoj strani sklopa (3),
and R8, for each occurrence, are, independently, -H, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted heterocyclyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl, or an optionally substituted heteroaralkyl; 
Rio 1 Riuj,su u svakom slučaju nezavisno -H, opcijski supstituirani alkil, opcijski supstituirani alkenil, opcijski supstituirani alkinil, opcijski supstituirani cikloalkil, opcijski supstituirani cikloalkenil, opcijski supstituirani heterociklil, opcijski supstituirani aril, opcijski supstituirani heteroaril, opcijski supstituirani aralkil, ili opcijski supstituirani heteraralkil; ili Rio 1 Ruičine zajedno sa dušikom za koji su vezani opcijski supstituirani heterociklil ili opcijski supstituirani heteroaril;
Many pharmaceutical active ingredients, in addition to having excellent activity in their appropriate application, also have abuse potential, i.e. they can be used by an abuser to bring about effects other than those intended. 
Veliki broj farmaceutskih djelatnih tvari ima pored odlične učinkovitosti na svom dotičnom području primjene i potencijal zlouporabe, to znači, može ih primijeniti zlorabitelj, da prouzroči djelovanja, koja ne odgovaraju propisanoj svrsi.
According to one embodiment the feed water is desalinated seawater, brackish water or brine, treated wastewater or natural water such as ground water, surface water or rainfall. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je ulazna voda desalinirana morska voda, boćata voda ili rasol, obrađena otpadna voda ili prirodna voda poput podzemne vode, površinske vode 1li kišnice.
The solid-state lighting apparatus (100; 200; 300; 400; 500; 600; 700; 800; 900) of claim 1, wherein the at least one solid state light emitting source (120; 220; 420; 520; 620; 720; 820; 920) is selected from a group of low power or high power LEDs including LED, OLED, and PLED. 
Rasvjetni uređaj, čvrstog oblika tijela (100; 200; 300; 400; 500; 600; 700; 800; 900) prema zahtjevu 1, naznačen time da najmanje jedan izvor svjetlosti čvrstog tijela (120; 220; 420; 520; 620; 720; 820; 920) je odabran iz skupine LED dioda male ili visoke snage, uključujući LED, OLED 1 PLED.
A compound of formula (5): wherein R1 represents an alkyl group, such as a C1-6 alkyl group, and preferably an isopropyl group; 
. Ne gt gdje R' predstavlja alkil grupu, kao što je C,alkil grupa i poželjno izopropil grupa;
The wet mass was dried in a tray dryer at 70° C. till the loss on drying was 1.48%. 
Vlažna masa je osušena u sušioniku s kadicom na 70 "C sve dok gubitak pri sušenju nije bio 1,48 %.
subsequently incorporating said expanding agent in said polymeric composition in the molten state; ii) if said vinyl aromatic polymer and/or copolymer (a) is already in the molten state, adding said polyolefin or polyolefin copolymer (b) in the amount ranging from 1% to 50% by weight, said olefinic elastomer grafted with said vinyl aromatic polymer (c) in the amount ranging from 0.01% to 40% by weight and then incorporating said expanding agent so as to form the polymeric composition. 
2. - zatim uključivanje sredstva za širenje u navedeni polimerni sastav u rastaljenom stanju; ii) ukoliko su vinil aromatski polimer i/ili vinil aromatski kopolimer (a) već u rastaljenom stanju, dodavanje poliolefina (b) u količini u rasponu od barem 1 % po masi, cijepljenog olefinskog elastomera (c) u količini u rasponu od 0,01 % do 40 % po masi te zatim uključivanje sredstva za širenje kako bi se dobio polimerni sastav.
The ActRII-Fc fusion protein for use of claim 1, wherein the amino acid sequence of the ActRII-Fc fusion protein consists of SEQ ID NO: 21. 
aminokiselinska sekvenca SEQ ID NO:21 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 21.
A method according to claim 1 such that the phosphonic acid salt is prepared in advance or formed in situ within the treatment composition, in the presence of the corresponding base. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se sol fosfonske kiseline priprema unaprijed ili nastaje in situ u pripravku za tretiranje, u prisutnosti odgovarajuće baze.
A multivalent immunogenic composition comprising Streptococcus pneumoniae capsular saccharide conjugates of serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F and 23F and a pharmaceutically acceptable excipient, wherein each of the serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 22F and 23F is conjugated to a carrier protein independently selected from the group consisting of tetanus toxoid (TT), diphtheria toxoid (DT), CRM-197, fragment C of TT, PhtD, PhtBE or PhtDE fusions, detoxified pneumolysin and protein D, and wherein the 19A and 19F is each independently conjugated to diphtheria toxoid or to CRM197, wherein the 19A capsular saccharide is directly conjugated to the carrier protein. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumoniae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 1, 4, 5, 6B, 7F, 9V, 14, 18C i 23F iz kapsule bakterije S. pneumoniae, gdje je prvi bakterijski toksoid različiti protein u odnosu na drugi bakterijski toksoid.
one to six contiguous amino acids corresponding to the two to six contiguous amino acids immediately N terminal to said residues in the sequence of the protein from which the peptide derives; and/or 
da rečeni peptid ima poboljšanu sposobnost izazivanja tolerancije kod pojedinca u usporedbi s dimeričkim oblikom rečenog peptida; i/ili da izvorni odsječak regije sadrži najmanje jedan ostatak cisteina; i/ili
The powder was then heated in an oven to 1200° C. for the crystal to grow to the size of 100 nm, which is the critical size for 1.5% Y2O3 stabilized zirconia. 
Prašak je zatim zagrijavan u peći pri 1200 "C za rast kristala do veličine od 100 nm, koja je kritična veličina za cirkonijev oksid stabiliziran sa 1.5% Y2O;.
The compounds of claim 1 wherein R2 is a substituent selected from the group consisting of hydrogen, C1-4alkyl, hydroxy(C1-4)alkyl, and phenyl(C1-6)alkoxy(C1-4)alkyl; 
Spoj prema zahtjevu 1 naznačen time da R2 je supstituent izabran iz skupine koju čine vodik i C1-4alkil.
The composition of claim 1, wherein the daily dosage is 480 mg active substance. The composition of claim 1, wherein the the dosage form contains 120, 180 or 240 mg active substance. 
Sastav iz patentnog zahtjeva 1, pri čemu je količina u obliku doziranja 90, 120, 180, 240 ili 360 mg dimetilfumarata.
The method according to Claim 18; wherein the antigen is loaded onto class II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell. 
Metoda prema Zahtjevu 13, gdje je antigen uklopljen u MHC molekule razreda II prikazan na površini prikladne stanice koja prikazuje antigen putem kontakta dovoljne količine antigena sa spomenutom stanicom.
Each ball spline nut 42, 43 is generally cylindrical, hollow and has a pair of opposed sides. 
Svaka od kuglasto-klinastih matica (42), (43) je u principu cilindričnog oblika, šuplja i ima dvije suprotne strane.
r and s are independently an integer comprised between 1 and 3; with q + r+ s≥4; in the presence of a Fe(acac)3 in an aprotic solvent such as THF or NMP at a temperature ranging from 0°C to RT. 
Tis su neovisno cijeli brojevi, koji se kreću između 1 i3; gdjeq+r1+s 24; u prisutnosti Fe(acac); u neprotonskom otapalu, poput THF ili NMP, na rasponu temperatura od 0 *C do sobne temperature.
A compound for use of Claim 25 wherein the therapy is the treatment of prevention of chronic obstructive pulmonary disease. 
Spoj za uporabu prema patentnom zahtjevu 25 naznačen time što terapija je liječenje ili prevencija kronične opstruktivne bolesti pluća.
The radio communication system according to claim 1, wherein the uplink synchronous status is managed by a timer so that the uplink synchronous status is sustained until the timer expires. 
Uređaj mobilne stanice (50) prema zahtjevu 1 ili 2, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena koja je uključena u primljenom odgovoru slučajnog pristupa (S02).
(iv) at least one light chain variable region, said light chain variable region comprising: 
najmanje jednu varijabilnu regiju lakog lanca, spomenuta varijabilna regija lakog lanca obuhvaća:
The method of claim 1, wherein said sustained release composition provides a release profile to obtain a CavSS of about 15 ng/ml to about 35 ng/ml. 
Sastav prema bilo kojem od zahtjeva 1 do 3, koji osigurava C,,gg Od 15 ng/ml do 35 ng/ml.
Use according to embodiment 11, characterised in that a top-up dose of fentanyl is administered not earlier than 5 minutes after the precedent fentanyl dose. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 7, naznačen time što se dopunska doza fentanila ne daje ranije od 5 minuta nakon prethodne doze fentanila.
The lipid particle for use of claim 13, wherein the administration is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intra-articular, intralesional, intratracheal, subcutaneous, and intradermal. 
Čestica lipida za uporabu u skladu s patentnim zahtjevom 13, naznačena time, da je primjena odabrana iz skupine koju čine oralni, intranazalni, intravenski, intraperitonealni, intramuskularni, intraartikularni, intralezionalni, intratrahealni, subkutani i intradermalni.
The compound of claim 2, wherein the half-life extending moiety is selected from Fc, FcRn binding ligand, albumin, albumin-binding ligand, transferrin, a polyethylene glycol (PEG) moiety, a polypropylene glycol (PPG) moiety, a PAS moiety, and a hydroxyethyl starch (HES) moiety. 
Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time što je spoj kovalentno vezan dijelom koji produžuje poluživot, izborno pri čemu je dio koji produžuje poluživot odabran od Fc, FcRn vezujućeg liganda, albumina, albumin-vezujućeg liganda, transferina, PEG dijela, PPG dijela, PAS dijela te HES dijela.
It is contemplated that the compounds will be useful in therapy as pharmaceuticals, in particular for the treatment of substance withdrawal disorders associated with glutamate dysfunction in an animal and particularly in a human. 
Uporaba spoja prema bilo kojem zahtjevu 1, 2, 3 ili 4 naznačena time da je za proizvodnju medikamenta za liječenje neuroloških i psihijatrijskih poremećaja povezanih s glutamatnom disfunkcijom.
A pharmaceutical composition which is a tablet comprising the p -toluenesulfonic acid salt of 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide as active agent in a portion of at least 55% by weight of the composition. 
PATENTNI ZAHTJEVI L m» Farmaceutski pripravak naznačen time da je tableta koja sadrži p-toluensulfonsku kiselu sol 4£4-[3-(4-kloro-3- trifluorometilfenil)-ureido]-fenoksi)-piridin-2-karboksilne kiselina metil amida kao aktivno sredstvo koje ima udio od najmanje 55% težinski pripravka.
a hydrogen atom or C1-C6 alkyl group, branched or unbranched, saturated or unsaturated, substituted or unsubstituted; the groups R1 and R2 may also form a heterocycle, 
- RIiR2 neovisno jesu: vodikov atoma ili C,-Cs-alkilna skupina, koja može biti razgranana ili ravnolančasta, zasićena ili nezasićena; skupine R' i R* također mogu tvoriti haterociklički prsten,
This equipment serves basically for the purpose of extrusion-spheroidization, centrifugal granulation, fluidization rotogranulation and high-shear mixing processes. 
Ovaj uređaj služi u osnovi za ekstrudiranje-sferoidizaciju, centrifugalno granuliranje, fluidizacijsko rotacijsko granuliranje i 'high-shear' postupke miješanja.
The insoluble materials formed were filtered and the filtrate concentrated. 
Formirani netopljivi materijali su filtrirani i filtrat je koncentriran.
for use in treating diabetes or reducing body weight in a human comprising once weekly parenteral administration wherein said administration achieves a mean steady state plasma concentration of the exendin-4, the exendin-4 analog, or the exendin agonist analog of 170 pg/ml to 600 pg/ml for at least one month. 
davanje pripravka čovjeku jednom tjedno; i davanje pripravka dovoljnu za održavanje kontinuirane minimalne plazma koncentracije eksendina ili analognog agonista eksendina od oko 170 pg / ml do oko 600 pg / ml u trajanju od najmanje 1 mjeseca.
A chemically modified glycosaminoglycan, which glycosaminoglycan is selected from the group consisting of heparin and heparan sulfate, and which chemically modified glycosaminoglycan has: 
Kemijski modificiran glikozaminoglikan, naznačen time da se glikozaminoglikan bira iz skupine koja se sastoji od heparina i heparan sulfata, te što kemijski modificiran glikozaminoglikan ima:
A compound selected from the group consisting of 
Spoj izabran iz grupe koja obuhvaća
A molecule that binds to activated hepatocyte growth factor B chain and inhibits specific binding of said activated HGF B chain to c-met, wherein said molecule is: 
Molekula koja se veže na B lanac aktivirnog hepatocitnog faktora rasta i inhibira specifično vezanje spomenutog aktiviranog HGF B lanca na c-met, naznačena time, da spomenuta molekula je:
NATP is compound (II) wherein R2 is an amino group. 
Spoj iz patentnog zahtjeva 4, gdje R2 je amino grupa, ili njegova sol.
The pooling device of claim 6, wherein said fluid connection assembly [104] includes a first force-activated valve [182] being connected to said outlet port of said pooling device for selectively regulating a directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži prvi ventil koji se aktivira silom [182] koji je spojen na navedeni izlazni otvor navedenog uređaja za objedinjavanje radi selektivnog reguliranja usmjerenog fluidnog strujanja fluida.
The valve element 5 is biased into the first position. 
Element ventila 5 je prenapregnut u prvi položaj.
the pharmaceutical composition is formulated for intravenous, intratumoral, intraarterial, topical, intraocular, ophthalmic, intracranial, intrathecal, intravesicular, intradermal, subcutaneous, intramuscular, intranasal, intratracheal, pulmonary, intracavity, or oral administration; the pharmaceutically acceptable carrier is a sugar or a protein, optionally wherein the sugar is selected from the group consisting of sucrose, glucose, mannitol, and a combination thereof, and is present in the pharmaceutical composition at a concentration from about 5% to about 20%, optionally wherein the protein is albumin; and/or 
Farmaceutski spoj prema patentnom zahtjevu 10, pri čemu je a) farmaceutski spoj formuliran je za intravensku, intratumornu, intraarterijsku, topičku, intraokularnu, oftalmičku, intrakranijalnu, intratekalnu, intravezikularnu, intradermalnu, subkutanu, intramuskularnu, intranazalnu, intratrahealnu, pulmonarnu, intrakavitalnu ili oralnu primjenu; b) farmaceutski prihvatljiv nosač je šećer ili protein, pri čemu se opcijski odabire šećer iz skupine koja se sastoji od saharoze, glukoze, manitola i njihove kombinacije, a prisutan je u farmaceutskom pripravku u koncentraciji od oko 5 % do oko 20 %; i/ili protein albumin; i/ili c) je farmaceutski spoj liofiliziran.
A pharmaceutical composition or article of manufacture according to claim 28, comprising the following ingredients: rFSH, Poloxamer 188, sucrose, methionine, m-cresol, and an aqueous phosphate buffer at a pH of at or about 7.0. 
. Farmaceutski pripravak ili pripravak prema zahtjevu 29 naznačen time da sadrži sljedeće sastojke: rFSH, poloksamer 188, saharozu, metionin, m-kresol, i vodeni fosfatni pufer vrijednosti pH od ili oko 7.0.
The container of claim 9 wherein the agitating means (108) is one or more blades rotatably coupled to a mixer base (110). 
Posuda prema zahtjevu 9, naznačena time, što je dio za miješanje (108) jedna ili više oštrica koje su spojene na bazu (110) miksera na način da se mogu okretati.
Process for manufacturing high solids aqueous suspensions of mineral materials) comprising the steps of: 
Postupak proizvodnje vodenih suspenzija mineralnih materijala s visokim udjelom krutina koji sadrži korake:
Y is selected from the group consisting of ketal, ester, carbamate optionally substituted with a saturated or unsaturated C1 to C6 alkyl group, ether, and amide optionally substituted with a saturated or unsaturated C1 to C6 alkyl group; and 
Y je odabran iz skupine koja se sastoji od ketala, estera, karbamata po izboru supstituiranog sa zasićenim ili nezasićena C, do Cg alkilna skupina, eter i amid, po izboru supstituiran sa zasićenom ili nezasićenom C; do C% alkilnom skupinom
and R5' are hydrogen or C1-7-alkyl; or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
i R5’ su vodik ili C1−7−alkil; ili njegova farmaceutski prihvatljiva sol ili kisela adicijska sol, racemična smjesa ili njegov odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
is or phenyl, wherein said phenyl is optionally substituted with R6; 
GO m fenil, pri čemu je navedeni fenil proizvoljno sngstituiiran s R';
propelling the plow moldboards-first on the deck of a vessel toward and across a fulcrum on a stern of the vessel; 
pokretanja prvo odgrnjača pluga (100,) na palubi plovila prema i preko uporišta na krmi plovila;
The pharmaceutical composition of claim 4, further comprising at least one other anti-cancer therapy agent. 
Farmaceutski sastav iz patentnog zahtjeva 4, nadalje obuhvaća najmanje jedan različiti terapijski agens protiv raka.